检索
AI 对话
AI 辅写
analysis
趋势分析
编组
开放平台
more
更多
排名必读论文期刊顶会热点AI 简史溯源树小脉星探人才迁徙塔尖人才国防情报追踪开源工具智慧手语
VIPCreated with Sketch.

361 Phase I, open-label, dose-escalating clinical and pharmacokinetic study of the novel antimicrotubulin agent PM060184 administered over 10 minutes on days 1-3 and 15-17 every 28 days to patients with advanced malignant solid tumors

Manuel Hidalgo,Valentina Boni,Anthony W. Tolcher,L. Smith,A. Cubillo,D. Rasco,Emiliano Calvo,A. Amaya,E. Ordoñez,A. Patnaik, S. Cerda,C. Coronado,S. Fudio,B. Miguel-Lillo,R. Prados, O. Ortega,A. Soto-Matos, K.P. Papadopoulos

EUROPEAN JOURNAL OF CANCER（2015）

引用 3|浏览19
暂无评分
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要